Administration of Myelin Basic Protein Peptides Encapsulated in Mannosylated Liposomes Normalizes Level of Serum TNF-α and IL-2 and Chemoattractants CCL2 and CCL4 in Multiple Sclerosis Patients
We have previously shown that immunodominant MBP peptides encapsulated in mannosylated liposomes (Xemys) effectively suppressed experimental allergic encephalomyelitis (EAE). Within the frames of the successfully completed phase I clinical trial, we investigated changes in the serum cytokine profile...
Main Authors: | Lomakin, Yakov, Belogurov, Alexey, Glagoleva, Irina, Stepanov, Alexey, Zakharov, Konstantin, Okunola, John, Smirnov, Ivan, Genkin, Dmitry, Gabibov, Alexander |
---|---|
Format: | Online |
Language: | English |
Published: |
Hindawi Publishing Corporation
2016
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864531/ |
Similar Items
-
CD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line Disease-Modifying Therapies: A First-in-Human, Proof-of-Concept Dose-Escalation Study
by: Belogurov, Alexey, et al.
Published: (2016) -
Liposome-encapsulated peptides protect against experimental allergic encephalitis
by: Belogurov, Alexey A., et al.
Published: (2013) -
Ubiquitin-independent proteosomal degradation of myelin basic protein contributes to development of neurodegenerative autoimmunity
by: Belogurov, Alexey, et al.
Published: (2015) -
Mannosylated liposomes for targeted gene delivery
by: Kong, Fansheng, et al.
Published: (2012) -
Glatiramer Acetate and Nanny Proteins Restrict Access of the Multiple Sclerosis Autoantigen Myelin Basic Protein to the 26S Proteasome
by: Kuzina, Ekaterina, et al.
Published: (2014)